BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Simon J Hogg; Andrea Newbold; Stephin J Vervoort; Leonie A Cluse; Benjamin P Martin; Gareth P Gregory; Marcus Lefebure; Eva Vidacs; Richard W Tothill; James E Bradner; Jake Shortt; Ricky W Johnstone

Journal article

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Simon J Hogg, Andrea Newbold, Stephin J Vervoort, Leonie A Cluse, Benjamin P Martin, Gareth P Gregory, Marcus Lefebure, Eva Vidacs, Richard W Tothill, James E Bradner, Jake Shortt, Ricky W Johnstone

Molecular Cancer Therapeutics | AMER ASSOC CANCER RESEARCH | Published : 2016

DOI: 10.1158/1535-7163.MCT-15-0924

University of Melbourne Researchers

Jake Shortt Author The Sir Peter MacCallum Department of Oncology

Richard Tothill Author Clinical Pathology

Ricky Johnstone Author The Sir Peter MacCallum Department of Oncology

Andrea Newbold Author The Sir Peter MacCallum Department of Oncology

Related Projects (2)

Cancer Genetics, Epigenetics And Targeted Therapies

I aim to gain greater insight into how blood cancers arise and how we should ultimately treat patients with these diseases. I will identify ..

2007 Program Grant - (Immune Regulation, Effector Function And Human Immunotherapy)

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

Grants

Awarded by NHMRC

Funding Acknowledgements

This work was supported by funding from the Leukemia Foundation of Australia (to S.J. Hogg, A. Newbold, G.P. Gregory, and M. Lefebure), the Cancer Therapeutics CRC (to S.J. Hogg and G.P. Gregory), the Royal Australasian College of Physicians (to G.P. Gregory), and the Arrow Bone Marrow Transplant Foundation (to M. Lefebure). J. Shortt is supported by funding from the Eva and Les Erdi/ Snowdome Foundation Victorian Cancer Agency Fellowship, and the Cancer Council Victoria. R.W. Johnstone is a senior principal research fellow (APP1077867) of the National Health and Medical Research Council of Australia (NHMRC) and is supported by an NHMRC program grant (APP454569), the Cancer Council Victoria and the Victorian Cancer Agency.